Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03095248
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:53.502442+00:00
Published At
2025-04-22T00:00:00+00:00
Record Updated At
2025-04-22
Results Posted At
2025-04-22
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Neurofibromatosis 2", "Vestibular Schwannoma", "Meningioma", "Ependymoma", "Glioma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-04-22"
protocolSection.identificationModule.nctId
"NCT03095248"
protocolSection.identificationModule.officialTitle
"Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-04-22"

Study condition terms

  • Neurofibromatosis 2 (protocolSection.conditionsModule.conditions)
  • Vestibular Schwannoma (protocolSection.conditionsModule.conditions)
  • Meningioma (protocolSection.conditionsModule.conditions)
  • Ependymoma (protocolSection.conditionsModule.conditions)
  • Glioma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.